Novel Tubulin Polymerization Inhibitors Overcome Multidrug Resistance and Reduce Melanoma Lung Metastasis
暂无分享,去创建一个
Duane D. Miller | J. Dalton | Sunjoo Ahn | Jin Wang | Yan Lu | Wei Li | V. Loveless | Chien-Ming Li | Jianjun Chen | Zhao Wang
[1] A. Sonnenberg,et al. Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. , 2011, Blood.
[2] C. Robert,et al. New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.
[3] A. Hauschild,et al. Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[4] D. Roukos. PLX4032 and melanoma: resistance, expectations and uncertainty , 2011, Expert review of anticancer therapy.
[5] Duane D. Miller,et al. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer , 2011, Cancer Chemotherapy and Pharmacology.
[6] Duane D. Miller,et al. Drug Metabolism and Pharmacokinetics of 4-Substituted Methoxybenzoyl-aryl-thiazoles , 2010, Drug Metabolism and Disposition.
[7] Duane D. Miller,et al. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. , 2010, Journal of medicinal chemistry.
[8] T. Satou,et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway , 2010, Journal of experimental & clinical cancer research : CR.
[9] E. Pasquier,et al. MVL-PLA2, a Snake Venom Phospholipase A2, Inhibits Angiogenesis through an Increase in Microtubule Dynamics and Disorganization of Focal Adhesions , 2010, PloS one.
[10] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[11] Wei Li,et al. Identifying Novel Molecular Structures for Advanced Melanoma by Ligand-Based Virtual Screening , 2009, J. Chem. Inf. Model..
[12] Duane D. Miller,et al. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. , 2009, Journal of medicinal chemistry.
[13] Duane D. Miller,et al. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3β, 17α, 20-triol and their bioactivity in melanoma cells , 2009, Steroids.
[14] Jinsong Liu,et al. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. , 2008, Cancer research.
[15] P. Nikolinakos,et al. The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] M. Caraglia,et al. The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? , 2008, The Journal of investigative dermatology.
[17] J. Maris,et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors , 2008, Clinical Cancer Research.
[18] B. Bhattacharyya,et al. Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulin , 2008, Medicinal research reviews.
[19] Duane D. Miller,et al. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. , 2007, Bioorganic & medicinal chemistry letters.
[20] R. Marais,et al. Melanoma biology and new targeted therapy , 2007, Nature.
[21] Jianping Chen,et al. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.
[22] Steve Y. Cho,et al. A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors , 2006, Clinical Cancer Research.
[23] Lei Xu,et al. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[24] Jian Ding,et al. Pseudolarix Acid B, a New Tubulin-Binding Agent, Inhibits Angiogenesis by Interacting with a Novel Binding Site on Tubulin , 2006, Molecular Pharmacology.
[25] E. Voest,et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Woltering,et al. Colchicine and 2-methoxyestradiol Inhibit Human Angiogenesis. , 2005, The Journal of surgical research.
[27] H. Gourdeau,et al. Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics , 2004, Clinical Cancer Research.
[28] Patrick A. Curmi,et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.
[29] I. Catalá,et al. Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.
[30] S. Ng,et al. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. , 2000, BioTechniques.
[31] F. Cognetti,et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. , 2000, Journal of experimental & clinical cancer research : CR.
[32] Wan Ariffin Bin Abdullah,et al. Med Pediatr Oncol , 1999 .
[33] L. Xue,et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. , 1999, Cancer biotherapy & radiopharmaceuticals.
[34] W. Berger,et al. Possible role of the multidrug resistance‐associated protein (MRP) in chemoresistance of human melanoma cells , 1997, International journal of cancer.
[35] D. Guénard,et al. [Taxotere: from yew's needles to clinical practice]. , 1993, Bulletin du cancer.
[36] G. Jacobsen,et al. Chemotherapy of a human malignant melanoma transplanted in the nude mouse. , 1975, Cancer research.
[37] Duane D. Miller,et al. Biological activity of 4-substituted methoxybenzoyl-aryl-thiazole: an active microtubule inhibitor. , 2011, Cancer research.
[38] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[39] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[40] S. Cohen. Chemotherapy of metastatic melanoma. , 1992, The Mount Sinai journal of medicine, New York.
[41] S. Salmon. Human tumor clonogenic assays: growth conditions and applications. , 1986, Cancer genetics and cytogenetics.
[42] R. Nelson. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. , 1982, Medical and pediatric oncology.